share_log

透云生物(01332)发布中期业绩 股东应占亏损8395.1万港元 同比收窄4.67%

Touyun Biotech (01332) Announces Interim Results, Shareholders' Share of Loss of HK$83.951 million narrowed 4.67% year-on-year

Zhitong Finance ·  Aug 25, 2023 10:08

Zhitong Financial APP News, Touyun Bio (01332) released its interim results for the six months ended June 30, 2023. During the period, the group achieved HK $104 million in income from the sale of goods and services provided, down 37.17% from the same period last year; the loss attributable to shareholders was HK $83.951 million, down 4.67% from the same period last year; and the basic loss per share was HK2.99 cents.

According to the announcement, the narrowing of the loss was mainly due to a decrease in revenue due to a decrease in orders from major customers and offset by a reduction in financial costs.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment